Navigation Links
Genomas Expands Personalized Medicine Business with Clinical Laboratory Licenses in New York, Florida, California

HARTFORD, Conn., March 4, 2013 /PRNewswire/ -- Genomas®, a biomedical company delivering personalized medicine to modern clinical practice, has been awarded clinical laboratory licenses in three of the most populous States. The company's Laboratory of Personalized Health received licenses from the New York Department of Health, the Florida Agency for Health Care Administration, and the California Department of Public Health.

Gualberto Ruano , M.D., Ph.D., President of Genomas and Director of the Laboratory of Personalized Health (LPH) stated: "New York, Florida, and California are among the most demanding States in terms of laboratory technical expertise and business credentialing. Now we are determined to bring our clinical pharmacogenetics services to the people of these States and the entire nation." These key markets herald a national platform for Genomas products in personalized healthcare, medical decision-support and clinical genomic diagnostics.

LPH was certified previously by the Centers for Medicare and Medicaid Services (CMS) under CLIA (Clinical Laboratory Improvement Amendments, and was licensed by the CT Department of Public Health in 2005. In 2012, Genomas had attained credentialing as a Medicare provider and began providing services in Texas and Pennsylvania.

More than 500 clinicians and 5000 patients in Connecticut have already benefited from the Genomas HILOmet PhyzioType® System, which allows personalized management of over 250 drugs to treat mental illness, pain, diabetes, and heart disease. Clinicians access the information through the Personalized Health Portal, which is a secure web-based interface providing data on over 250 different medications. The clinical support extends to 130 neuro-psychiatric drugs (antidepressants, neuroleptics, anticonvulsants, anxiolytics, stimulants, analgesics, hypnotics) and 120 cardio-metabolic drugs (to treat hypertension, diabetes, angina, thrombosis, gastro-esophageal reflux disease, erectile dysfunction, asthma).

In CT, Genomas has established a successful distribution and customer support partnership with Clinical Laboratory Partners (CLP). James Fantus , President and CEO of CLP, and Vice President of Hartford Healthcare Corporation, commented: "It is a great satisfaction to witness a national platform developing through Genomas from Hartford Healthcare partnerships, which include Clinical Laboratory Partners, Hartford Hospital, Institute of Living, and Hospital of Central Connecticut. Genomas is leading Connecticut to national prominence in the clinical practice of personalized medicine."

Please visit for more information.

SOURCE Genomas
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. UV Flu Technologies Expands Its International Footprint
2. Nabsys Expands Leadership Team to Prepare for Commercialization of Novel DNA Positional Sequencing Technology
3. Ansell Limited Expands Korean Presence
4. Premier Research Expands Salt Lake City and Phoenix Testing Facilities Adding 50% Capacity
5. Groundbreaking National Program to Reverse Obesity Expands to 50 Locations
6. Good Start Genetics Announces $14M Series B Financing, Expands Senior Management Team
7. IntelliCell BioSciences Expands Management Team
8. Questcor Pharmaceuticals Expands Repurchase Program
9. CuraLase Expands with New Franchise in Texas
10. BioNeutral Group Expands The Testing Of Its Ygiene Sterilant Against Anthrax Spores
11. Medtech Expands Nursing Education Opportunities In Florida
Post Your Comments:
(Date:6/27/2016)... N.C. (PRWEB) , ... June 27, 2016 , ... ... commercial operations for Amgen, will join the faculty of the University of ... as adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus ...
(Date:6/24/2016)... on a range of subjects including policies, debt and investment ... Speaking at a lecture to the Canadian Economics ... the country,s inflation target, which is set by both the ... "In certain areas there needs to be frequent ... not sit down and address strategy together?" He ...
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal ... Their findings are the subject of a new article on the Surviving Mesothelioma website. ... the blood, lung fluid or tissue of mesothelioma patients that can help point doctors ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
Breaking Biology Technology:
(Date:6/22/2016)... June 22, 2016   Acuant , ... verification solutions, has partnered with RightCrowd ® ... for Visitor Management, Self-Service Kiosks and Continuous ... that add functional enhancements to existing physical ... and venues with an automated ID verification ...
(Date:6/16/2016)... 16, 2016 The global ... to reach USD 1.83 billion by 2024, according ... Inc. Technological proliferation and increasing demand in commercial ... to drive the market growth.      ... The development of advanced multimodal techniques for biometric ...
(Date:6/7/2016)... June 7, 2016  Syngrafii Inc. and San ... relationship that includes integrating Syngrafii,s patented LongPen™ eSignature ... This collaboration will result in greater convenience for ... union, while maintaining existing document workflow and compliance ... ...
Breaking Biology News(10 mins):